Scholarlink

Purpose <p>The metronomic principle of chemotherapy for malignancies, using frequent small doses, has been suggested to show superior efficacy compared with classical administration. Thus, we aimed at investigating whether treatment with Navelbine, according to the metronomic drug schedule, was superior to conventional oral treatment in terms of clinical efficacy and safety. EUDRACT no: 2016-002165-63.</p> Methods <p>The NAME-trial was an open label, randomized, multicenter phase II study. We included 163 patients with metastatic breast cancer in Denmark between 2017 and 2022. All participants were randomized between standard treatment in arm A with classical per oral Vinorelbine day 1 and day 8, every three weeks, or in arm B metronomic treatment with per oral Vinorelbine given as daily doses.</p> Results <p>The distribution of patients was well balanced between the two treatment arms. The median age was 68–69&#xa0;years in both arms, with a good performance status at study entry. We found a median progression-free survival (PFS) in arm A of 3.9&#xa0;months and a median PFS in arm B of 2.3&#xa0;months (P = 0.236). The median overall survival (OS) was 16.6&#xa0;months in arm A and 15.1&#xa0;months in arm B (P = 0.355). The evaluation of the adverse events showed that both regimes were well tolerated without significant differences.</p> Conclusion <p>Our overall evaluation of the NAME-trial results showed that metronomic oral Navelbine is not superior to the standard treatment with Vinorelbine and without any significant differences concerning side effects.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A direct comparison of classical oral Navelbine vs metronomic Navelbine in metastatic breast cancer: results from the Danish Breast Cancer Group’s (DBCG) NAME-trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月11日

查看全文
  • Anne Sofie Brems-Eskildsen,
  • Julia Kenholm,
  • Annette Torbøl Brixen,
  • Jeanette Dupont Rønlev,
  • Lars Stenbygaard,
  • Hella Danø,
  • Mie Grunnet,
  • Erik Hugger Jakobsen,
  • Jeppe Neimann,
  • Sven Tyge Langkjer,
  • Jürgen Geisler

摘要

Purpose

The metronomic principle of chemotherapy for malignancies, using frequent small doses, has been suggested to show superior efficacy compared with classical administration. Thus, we aimed at investigating whether treatment with Navelbine, according to the metronomic drug schedule, was superior to conventional oral treatment in terms of clinical efficacy and safety. EUDRACT no: 2016-002165-63.

Methods

The NAME-trial was an open label, randomized, multicenter phase II study. We included 163 patients with metastatic breast cancer in Denmark between 2017 and 2022. All participants were randomized between standard treatment in arm A with classical per oral Vinorelbine day 1 and day 8, every three weeks, or in arm B metronomic treatment with per oral Vinorelbine given as daily doses.

Results

The distribution of patients was well balanced between the two treatment arms. The median age was 68–69 years in both arms, with a good performance status at study entry. We found a median progression-free survival (PFS) in arm A of 3.9 months and a median PFS in arm B of 2.3 months (P = 0.236). The median overall survival (OS) was 16.6 months in arm A and 15.1 months in arm B (P = 0.355). The evaluation of the adverse events showed that both regimes were well tolerated without significant differences.

Conclusion

Our overall evaluation of the NAME-trial results showed that metronomic oral Navelbine is not superior to the standard treatment with Vinorelbine and without any significant differences concerning side effects.